Bromodomain-containing 2 (BRD2) is a transcriptional regulator that is a member of the bromodomain and extra-terminal (BET) family.1 It is ubiquitously expressed and localizes to the nucleus. BRD2 is composed of two N-terminal bromodomains (BD1 and BD2) that bind acetylated lysine on histones, serving to couple histone acetylation marks to the transcriptional regulation of target promoters, and an extra-terminal domain that mediates chromatin interactions.1,2 BRD2 associates with transcription effector and regulator proteins, including RNA polymerase II, histone acetylases and deacetylases, and transcriptional co-activators and co-repressors to form a transcription complex that regulates the expression of genes involved in inflammation and cell proliferation.1,3 BRD2 also binds to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope (E) protein, a transmembrane protein involved in CoV virion assembly and pathogenesis of the related virus, SARS-CoV.4,5,6 The BD2 bromodomain of BRD2 contains four α-helices that form the binding site for the acetylated histone H4 tail.7 Point mutations of valine 329 (V329A) or asparagine (N382A) in the BD2 bromodomain eliminate BRD2 binding to acetylated histone H4 lysine 12 (H4K12Ac), and a point mutation of tyrosine 427 (Y427F) abolishes the association between BRD2 and STAT3.8,9 Cayman’s BRD2 bromodomain 2 (human, recombinant) protein can be used for ELISA, Western blot (WB), and binding assay applications.WARNING This product is not for human or veterinary use.
